ALNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Alnylam Pharmaceuticals Inc (ALNY) does not present a compelling buy opportunity for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock has shown recent price weakness, mixed analyst sentiment, and lacks strong positive catalysts or proprietary trading signals to justify immediate entry. Holding off for now is recommended.
The MACD histogram is positive (1.186) but contracting, indicating weakening momentum. RSI is neutral at 41.859, and moving averages are converging, signaling indecision. The stock closed below the pivot level (327.809) and is closer to the S1 support level (316.418), suggesting potential further downside. Overall, technical indicators do not provide a strong buy signal.
The company's Amvuttra drug continues to show strong revenue growth and patient momentum, which is a positive long-term driver. Analysts have highlighted the potential of the TTR market as a $10B+ opportunity.
Recent price weakness (-3.98% in regular trading) and mixed analyst sentiment, including downgrades and lowered price targets, reflect concerns about valuation and near-term headwinds. Financial performance in Q4 2025 showed a significant drop in net income (-322.56% YoY) and EPS (-310.77% YoY), which could weigh on investor confidence.
In Q4 2025, revenue increased significantly by 84.95% YoY to $1.097 billion, driven by strong product performance. However, net income and EPS declined sharply (-322.56% and -310.77% YoY, respectively), and gross margin dropped to 75.6% (-8.55% YoY). These mixed financial results raise concerns about profitability despite revenue growth.
Analyst sentiment is mixed. Recent downgrades include Jefferies lowering its rating to Hold with a price target of $330, citing valuation concerns. However, some analysts, like Canaccord and Freedom Capital, maintain Buy ratings with price targets in the $400+ range, citing strong product performance and long-term growth potential. The average price target has been lowered across the board, reflecting caution.
